Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Jun. 29, 2018

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 29, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.0	$	23.9	$	11.1	$	—
Equity securities	13.6		13.6		—		—
Foreign exchange forward and option contracts	0.6		0.6		—		—
	$	49.2	$	38.1	$	11.1	$	—

Liabilities:
Deferred compensation liabilities	$	39.8	$	—	$	39.8	$	—
Contingent consideration and acquired contingent liabilities	170.5		—		—		170.5
Foreign exchange forward and option contracts	0.4		0.4		—		—
	$	210.7	$	0.4	$	39.8	$	170.5



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	58.2	$	46.8	$	11.4	$	—

Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	289.2	$	0.1	$	42.7	$	246.4

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities



Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	2.3
Fair value adjustments	(29.1		)
Balance at June 29, 2018	$	170.5

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's debt, excluding capital leases, as of the end of each period:



	June 29, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		689.2		700.0		675.2
Variable-rate receivable securitization due July 2020	240.0		240.0		200.0		200.0
5.75% notes due August 2022	884.0		796.1		884.0		804.8
4.75% notes due April 2023	500.2		407.1		526.5		412.4
5.625% notes due October 2023	731.4		609.1		738.0		628.8
5.50% notes due April 2025	692.1		563.0		692.1		564.5
Revolving credit facility	450.0		450.0		900.0		900.0
Level 2
9.50% debentures due May 2022	10.4		10.9		10.4		10.9
8.00% debentures due March 2023	4.4		4.4		4.4		4.4
Term loan due September 2024	1,617.9		1,586.5		1,851.2		1,848.7
Term loan due February 2025	598.5		589.5		—		—
Level 3
ACOA loan due December 2028	1.7		1.7		—		—
Total debt	$	6,430.6	$	5,947.5	$	6,806.6	$	6,348.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
CuraScript, Inc.	46.5	%	57.0	%	46.8	%	55.9	%

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:



	June 29, 2018		December 29, 2017
CuraScript, Inc.	35.3	%	33.8	%

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
H.P. Acthar Gel	46.4	%	53.2	%	44.6	%	51.0	%
Inomax	20.8	%	20.9	%	22.5	%	21.9	%
Ofirmev	13.6	%	12.6	%	13.9	%	12.9	%